Who's who

3 Houston innovators to know this week

In honor of Labor Day, here are three Houston innovators who probably aren't taking the day off. Courtesy photos

It may be Labor Day, but some of the hardest working Houston innovators are probably still checking their email on their phones from the pool.

Here are this week's innovators to know around town.

Marie Myers, CFO of UiPath

Marie Myers is the CFO of UiPath. Courtesy of UiPath

Marie Myers is a self-proclaimed Houstonian, avid bike rider, and robotics nerd — for lack of a better word. She's had a 20-year career in tech — most roles based right here in town — and throughout her whole experience, robotics process automation has been the most exciting technology she's gotten to work with.

UiPath just opened an office in Houston earlier this year, and Myers serves the company as CFO. She first worked with UiPath on the client side of things, and the technology awed her. She says she jumped at the opportunity to join the organization.

"When I think about RPA, the world lights up for me," she says. "It's truly transformative."

Click here to read more about the company.

Marco Bo Hansen, chief customer officer at Sani nudge and his executive team

Marco Bo Hansen, right, the chief customer officer at Sani nudge. Courtesy of TMCx

The Sani nudge executives may not be from Houston, but we give the Denmark-based company a pass for all its success coming out of the Texas Medical Center's accelerator program earlier this year. Sani nudge is a medical device company that can better track and encourage hand sanitation. The company is headed to California after being selected for a prestigious program with the Mistletoe Foundation.

Dr. Marco Bo Hansen is the chief customer officer and says that he'll be vigilantly advocating that his Sani nudge colleagues and the Mistletoe researchers keep hospital patients and staff in mind as Sani nudge moves forward with its innovations.

"We have to make sure that our solutions always generate value to the end users and can easily be used by the clinicians, infection preventionists, and hospital managers," he says.

Click here to read more about the company.

Ashley Gilmore, CEO and co-founder of Tracts.co

When Ashley Gilmore was studying law — specifically for the purposes of going into oil and gas — it amazed him how non-digitized the industry was, especially the mineral buying process. Gilmore figured out a way how to use tech to make the process way easier — and cheaper.

Now, his company, Tracts, has a new land group that's growing at a revenue rate of 30 percent month to month. With more and more clients, Tracts engages more data. And, with more and more data, the product increases in value for his customers.

"For some of our clients, Tracts is now existential for their business," Gilmore says. "In other words, they wouldn't be able to operate on their current business model without Tracts."

Click here to read more about the company.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News